Search Results 621-630 of 18582 for alopecia

1. A Dose Escalation Study of HFB301001 in Adult Patients with Advanced Solid Tumors - Mayo Clinic

   - All grades of alopecia are acceptable; - Endocrine dysfunction on replacement therapy is acceptable. - Severe or unstable medical condition, including ...

2. Clinical trials - Oncology (Medical)

   Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia. Rochester, Minn., Mankato, Minn., Albert Lea, Minn ...

3. Expanded Access Program To Provide Abemaciclib (LY2835219) For The Treatment Of Metastatic Breast Cancer - Mayo Clinic

   ... alopecia and peripheral neuropathy. Have adequate organ function, including: Hematologic: absolute neutrophil count ≥1.5 × 10⁹/Liter (L), platelets ≥100 ...

4. Study Of Safety, Pharmacokinetic And Efficacy Of APG-5918 In Advanced Solid Tumors Or Lymphomas - Mayo Clinic

   ... alopecia or leukodermia * Has gastrointestinal conditions that could affect the absorption of APG-5918 in the opinion of the Investigator * Use of ...

5. Phase 1b Safety Study Of CMB305 In Patients With Locally Advanced, Relapsed, Or Metastatic Cancer Expressing NY-ESO-1 - Mayo Clinic

   Significant autoimmune disease with the exception of alopecia, vitiligo, hypothyroidism or other conditions that have never been clinically active or were ...

6. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann, M.D.. Otolaryngologist. Rochester ...

7. Study Of Durvalumab + Tremelimumab With Chemotherapy Or Durvalumab With Chemotherapy Or Chemotherapy Alone For Patients With Lung Cancer (POSEIDON). - Mayo Clinic

   Patients with vitiligo or alopecia;; Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement or psoriasis not ...

8. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann, M.D.. Otolaryngologist. Rochester ...

9. A Study to Evaluate Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC - Mayo Clinic

   Subjects with vitiligo or alopecia;; Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement;; Any chronic skin ...

10. ALPN-202 With PD-1 Inhibition In Advanced Malignancies - Mayo Clinic

    Recovery to Grade ≤ 1 for any non-laboratory toxicity resulting from previous anticancer therapy prior to first dose of ALPN-202 (except alopecia, hearing ...